Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Martin Clive Hutchings is active.

Publication


Featured researches published by Martin Clive Hutchings.


Bioorganic & Medicinal Chemistry Letters | 1999

4-pyridin-5-yl-2-(3,4,5-trimethoxyphenylamino)pyrimidines : Potent and selective inhibitors of ZAP 70

David Festus Charles Moffat; Peter G Davis; Martin Clive Hutchings; Jeremy Martin Davis; Daniel Berg; Mark James Batchelor; James E. Johnson; James O'Connell; Richard M. Martin; Tom Carabbe; Jean Delgado; Martin Perry

Activation of the tyrosine kinase ZAP 70 has been shown to be crucial to the transduction of the T-cell receptor signalling pathway, which leads ultimately to proliferation, cytokine gene expression and T-cell effector functions. A series of 2-phenylaminopyrimidines have been identified as potent and selective inhibitors of ZAP 70.


Journal of Organic Chemistry | 2008

Scalable Synthesis of the VEGF-R2 Kinase Inhibitor JNJ-17029259 Using Ultrasound-Mediated Addition of MeLi-CeCl3 to a Nitrile

Michael Reuman; Sandra Beish; Jeremy Davis; Mark James Batchelor; Martin Clive Hutchings; David F. C. Moffat; Peter J. Connolly; Ronald K. Russell

The preparation of the selective VEGF-R2 kinase inhibitor 10 (JNJ-17029259) is described in which the key precursor, 4-(5-isoxazolyl)benzonitrile, undergoes clean transformation to the corresponding cumylamine derivative with CeCl(3)-MeLi in THF. This high-yielding cerium mediated transformation is robust, reproducible, and readily scalable based on a requirement for the anhydrous CeCl(3) to be milled and subjected to ultrasound treatment prior to addition of methyllithium.


Archive | 1996

Substituted 2-anilinopyrimidines useful as protein kinase inhibitors

Peter David Davis; David Festus Charles Moffat; Jeremy Martin Davis; Martin Clive Hutchings


Archive | 2000

5-cyano-2-aminopyrimidine derivatives

Mark James Batchelor; David Festus Charles Moffat; Jeremy Martin Davis; Martin Clive Hutchings


Archive | 1997

2-PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION

Peter David Davis; David Festus Charles Moffat; Mark James Batchelor; Martin Clive Hutchings; David Mark Parry


Archive | 2013

TNF -Alpha Modulating Benzimidazoles

Daniel Christopher Brookings; Mark Daniel Calmiano; Ellen Olivia Gallimore; Helen Tracey Horsley; Martin Clive Hutchings; James Andrew Johnson; Boris Kroeplien; Fabien Claude Lecomte; Martin Alexander Lowe; Timothy John Norman; Joanna Rachel Quincey; James Thomas Reuberson; Matthew Duncan Selby; Michael Alan Shaw; Zhaoning Zhu; Anne Marie Foley


Archive | 2014

Imidazopyridine Derivatives as Modulators of TNF Activity

Jonathan Mark Bentley; Daniel Christopher Brookings; Julien Alistair Brown; Thomas Paul Cain; Praful Tulshi Chovatia; Anne Marie Foley; Ellen Olivia Gallimore; Laura Jane Gleave; Alexander Heifetz; Helen Tracey Horsley; Martin Clive Hutchings; Victoria Elizabeth Jackson; James Andrew Johnson; Craig Johnstone; Boris Kroeplien; Fabien Claude Lecomte; Deborah Leigh; Martin Alexander Lowe; James Madden; Joanna Rachel Quincey; Laura Claire Reed; James Thomas Reuberson; Anthony John Richardson; Sarah Emily Richardson; Matthew Duncan Selby; Michael Alan Shaw; Zhaoning Zhu


Archive | 1998

Substituted 2-anilinopryimidines useful as protein kinase inhibitors

Martin Clive Hutchings; Peter David Davis; David Festus Charles Moffat


Archive | 2009

Fused tricyclic thiophene derivatives as mek inhibitors

Daniel Christopher Brookings; Martin Clive Hutchings; Victoria Elizabeth Laing; Barry John Langham


Archive | 2001

1-sulfonyl substituted tryptophane derivatives and its use as integrin inhibitors

Sarah Catherine Archibald; David Festus Charles Moffat; Martin Clive Hutchings; Anne Marie Foley

Researchain Logo
Decentralizing Knowledge